News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Study Results Show Dose-Intensified Temozolomide Chemotherapy in the Adjuvant Setting Does Not Improve Survival in Patients with GBM


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Apparently. the standard schedule is better than the dose intensive schedule for GBM patients using Temodar.  However, what I would love to see is a trial comparing different lengths of treatment. This trial used up to 12 months of treatment.  Overall survivals were about 6 months after they stopped using the Temodar in either arm.  Doesn't make sense to me to stop at 1 year.


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Source: http://www.rtog.org/News/tabid/72/articleType/ArticleView/articleId/78/Study-Results-Show-Dose-Intensified-Temozolomide-Chemotherapy-in-the-Adjuvant-Setting-Does-Not-Improve-Survival-in-Patients-with-GBM.aspx

(Everything below this line is from VirtualTrials.com!)



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740